Friday, October 17, 2025

DEA Declares Cocaine Derivative Legal But Disagrees That Marijuana Should Be The Same

The Drug Enforcement Administration (DEA) is working on legalizing a cocaine derivative [18 F]FP-CIT, which is said to be a “diagnostic substance that is used in assisting the evaluation of adult patients with suspected Parkinsonian syndromes.”

“Based on consideration of all comments, the scientific and medical evaluation and accompanying recommendation of [the Department of Health and Human Services], and based on DEA’s consideration of its own eight-factor analysis, the Administrator finds that these facts and all relevant data demonstrate that [18 F]FP-CIT does not meet the requirements for inclusion in any schedule. As such, DEA is removing [18 F]FP-CIT form control under the [Controlled Substance Act (CSA)],” the agency declared.

But, even as the agency participates in a review of marijuana’s scheduling status ordered by the president, it is disregarding public submissions urging that cannabis, like the cocaine-derived substance it is now rescheduling, should be removed from federal authority.

Last year, the DEA suggested descheduling the chemical [18 F]FP-CIT and established a public comment period for people to weigh in. Advocates jumped on the bandwagon, requesting comparable treatment for marijuana due to the plant’s demonstrated medical usefulness.

The agency noted one commenter on the notice of proposed rulemaking who said they are opposed to decontrol the cocaine derivative, adding that “rescheduling cocaine, or any cocaine derivative, is a safety concern and such rescheduling would wrongly signal that cocaine is less harmful than cannabis.”

“DEA does not agree with the commenter’s concern about harm. [18 F]FP-CIT is derived from cocaine, a schedule II substance, via ecgonine, a schedule II substance,” the agency said.

The schedule II substance argument is the same on which the DEA is basing the rescheduling of the cocaine derivative, explaining that the chemical is similar to [123 I]ioflupane, known as DaTscan or [123 I]FP-CIT–a fellow schedule II substance which the DEA removed from CSA in September 2015.

A top Food and Drug Administration (FDA) official indicated late last month that the agency is looking into “what flexibilities we might have” in the federal government’s marijuana scheduling study, which Biden has mandated as a “very high priority.” The official also said that while FDA leads the scientific review, the DEA “has the final word” on any potential scheduling decision.

Marijuana–currently a Schedule I substance–is also difficult to be a subject of scientific research because of the restrictive status, the FDA official also noted.

Rahul Gupta, head of the White House Office of National Drug Control Policy, stated last month that Biden’s decision to issue a bulk cannabis pardon and direct the administrative review was “historic.” He also stated that there is “clearly” proof that marijuana has medical benefits.

Meanwhile, the DEA intends to more than double the amount of marijuana that may be lawfully synthesized for research in 2023, as well as dramatically raise the quota for psychedelics like psilocyn, LSD, and mescaline manufacturing. The agency further claimed that the increase in quota is proof that it supports rigorous study into the substances, but it has come under fire from advocates and scientists for policies that are seen as antagonistic to supporting studies.

A White House spokesperson confirmed to Marijuana Moment that Biden wants to approve a bipartisan marijuana research bill passed by Congress last week. The measure would give the US Attorney General 60 days to either approve or request additional information from a marijuana research applicant. It would also provide a more efficient route for researchers requesting larger quantities of cannabis.


Information for this briefing was found via Marijuana Moment and the sources mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

One Response

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

Military Seizes Power in Madagascar After President Flees

Altamira Gold Hits 395.5 Metres Of 0.4 g/t Gold At Maria Bonita

Related News

End of the Line: Secret Service Concludes White House Cocaine Investigation

The investigation into the mysterious presence of cocaine in the White House has reached a...

Friday, July 14, 2023, 12:23:00 PM

The Looming Issue of Convertible Debt in the Canadian Cannabis Sector

The Canadian cannabis sector has a looming problem that few people want to address. No,...

Wednesday, August 14, 2019, 03:20:44 PM

Dead Cat Bounce? Poking At The Cannabis Market

An unexplained bout of optimism came over the marijuana markets this past week, as the...

Sunday, October 6, 2019, 07:00:13 AM

DEA Asserts Final Authority in Marijuana Scheduling Review

The Drug Enforcement Administration (DEA) has emphasized its “final authority” in determining the scheduling of...

Thursday, January 4, 2024, 02:12:00 PM

Canada Wants Its Excise Taxes On Cannabis

Canada’s tax collection agency is taking action to retrieve outstanding excise duty payments from licensed...

Thursday, February 29, 2024, 11:41:00 AM